<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227757</url>
  </required_header>
  <id_info>
    <org_study_id>16-517</org_study_id>
    <nct_id>NCT03227757</nct_id>
  </id_info>
  <brief_title>Evaluation of Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation (TRILUMINATE)</brief_title>
  <acronym>TRILUMINATE</acronym>
  <official_title>Trial to Evaluate Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation (TRILUMINATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evalve</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Evalve</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate safety and effectiveness of the Tricuspid
      Valve Repair System (TVRS) for treating symptomatic moderate or greater tricuspid
      regurgitation (TR) in patients currently on medical management and who are deemed appropriate
      for percutaneous transcatheter intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single arm, multi-center study.

      A minimum of 75 subjects will be prospectively enrolled into this single arm study in
      approximately 25 sites, in Europe, Canada and the United States. Patients will be seen for
      follow-up visits at discharge (≤ 7 days post index procedure), 30 days, 6 months, 1,2,3
      years. Whereas, in United States patients will be followed-up till 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic Tricuspid Regurgitation Reduction at Least 1 Grade</measure>
    <time_frame>At 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Major Adverse Event (MAE)</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Major Adverse Event (MAE)</measure>
    <time_frame>At Discharge (≤ 7 days post index procedure)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Major Adverse Event (MAE)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Major Adverse Event (MAE)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Major Adverse Event (MAE)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Major Adverse Event (MAE)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Device or Procedure-Related Adverse Events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Lab assessment of change in Tricuspid Regurgitation (TR) Severity Grade</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Lab assessment of change in Tricuspid Regurgitation (TR) Severity Grade</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Lab assessment of change in Tricuspid Regurgitation (TR) Severity Grade</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Lab assessment of change in Tricuspid Regurgitation (TR) Severity Grade</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Lab assessment of change in Tricuspid Regurgitation (TR) Severity Grade</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Tricuspid Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Tricuspid Valve Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received TVRS will be included in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tricuspid Valve Repair System</intervention_name>
    <description>Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.</description>
    <arm_group_label>Tricuspid Valve Repair System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be 18 years or older at time of consent and must not be a member of a
             vulnerable population.

          2. Subject or a legally authorized representative must provide written informed consent
             prior to any trial related procedure.

          3. Subject must agree not to participate in any other clinical trial for a period of one
             year following the index procedure.

          4. In the judgment of the investigator at the site, the subject has been adequately
             treated per applicable standards, including for coronary artery disease, mitral
             regurgitation and heart failure at least 30-days prior to index procedure. The
             Eligibility Committee must concur that the subject has been adequately treated.

          5. New York Heart Association (NYHA) Functional Class II (conditional), III, or
             ambulatory IV

             a. Conditional - NYHA II will be allowed in subjects with severe or greater TR

          6. No indication for left-sided or pulmonary valve correction.

          7. The Local Heart Team concur that percutaneous transcatheter intervention is
             appropriate for the subject.

             Echocardiographic Inclusion Criteria:

          8. Subjects with moderate or greater (≥2+) Tricuspid Regurgitation determined by the
             assessment of a qualifying transthoracic echocardiogram (TTE) and transesophageal
             echocardiogram (TEE) confirmed by the Echocardiography Core Lab (ECL). The ECL will
             also confirm the tricuspid valve anatomy to be suitable for implantation. If any
             cardiac procedure(s) that may occur within 90-days of procedure, then TTE and TEE must
             be repeated prior to the index procedure.

          9. Subjects with tricuspid valve anatomy determined to be suitable for implantation
             determined by the site heart team

         10. Subjects with tricuspid valve anatomy evaluable by TTE and TEE

        Exclusion Criteria:

          1. Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint.

          2. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. Female subjects of child-bearing potential must have a
             negative pregnancy test done within 7 days prior to the index procedure per site
             standard test.

          3. Subjects with severe uncontrolled hypertension (Systolic blood pressure [SBP] ≥ 180
             mmHg and/or Diastolic blood pressure [DBP] ≥ 110 mm Hg)

          4. Subjects with Systolic Pulmonary Artery Pressure &gt; 60 mmHg (echo determined)

          5. Subjects with prior tricuspid valve leaflet surgery or any currently implanted
             prosthetic tricuspid valve, or any prior transcatheter tricuspid valve procedure.

          6. Subjects with Mitral Regurgitation moderate-severe or greater severity (≥3+)

          7. Subjects with Pacemaker or ICD leads that would prevent appropriate placement of TVRS
             Clip

          8. Subjects with active endocarditis or active rheumatic heart disease or leaflets
             degenerated from rheumatic disease.

          9. Subjects with MI or known unstable angina within prior 30 days prior to enrollment

         10. Subjects with percutaneous coronary intervention within prior 30 days prior to
             enrollment

         11. Subjects with hemodynamic instability defined as systolic pressure &lt; 90 mmHg with or
             without afterload reduction, cardiogenic shock or the need for inotropic support or
             intra-aortic balloon pump or other hemodynamic support device.

         12. Subjects with Cerebrovascular Accident (CVA) within prior 30 days prior to enrollment

         13. Subjects with chronic dialysis

         14. Subjects with bleeding disorders or hypercoagulable state

         15. Subjects with active peptic ulcer or active gastrointestinal (GI) bleeding

         16. Subjects with contraindication to dual antiplatelet and anticoagulant therapy.

         17. Subjects with life expectancy of less than 12 months due to non-cardiac conditions

             Echocardiographic Exclusion Criteria:

         18. Subjects with tricuspid stenosis

         19. Subjects with tricuspid valve calcification
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Georg Nickenig</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadia Bouhdi</last_name>
    <phone>479 94 10 37</phone>
    <phone_ext>+32</phone_ext>
    <email>nadia.bouhdi@av.abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mike Hsu</last_name>
    <email>mike.hsu@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Saibal Kar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Greenbaum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Sorajja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gilbert Tang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nord Laennec - Chu De Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Saint-Herblain</state>
        <zip>44 093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrice Guerin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bichat-Claude Bernard Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Michel Juliard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilian University of Munich (LMU)</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jorg Hausleiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schuchtermann Klinik</name>
      <address>
        <city>Bad Rothenfelde</city>
        <state>Lower Saxony</state>
        <zip>49214</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marek Kowalski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <state>North Rhine-Westphalia</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Georg Nickenig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin der Johannes Gutenberg-Universitat Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ralph Stephan von Bardeleben</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philipp Lurz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albertinen-Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22457</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joachim Schofer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele - Presidio Ferrarotto</name>
      <address>
        <city>Catania</city>
        <state>Catania (CT)</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corrado Tamburino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele University Hospital</name>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Colombo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denti Paolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Sant'Ambrogio</name>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Bedogni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Serra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical and Provincial Hospital of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marta Sitges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Prof. Stephan Windecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HerzKlinik Hirslanden - Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Corti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zurich (USZ)</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maurizio Taramasso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRILUMINATE</keyword>
  <keyword>Percutaneous transcatheter intervention</keyword>
  <keyword>Tricuspid regurgitation</keyword>
  <keyword>Tricuspid Valve Repair System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

